HOME   |    PDF   |   


Towards the design of epitope candidates for Coronavirus 2


Hasanain Abdulhameed Odhar*, Salam Waheed Ahjel, Suhad Sami Humadi



Department of pharmacy, Al-Zahrawi University College, Karbala, Iraq



Hasanain Abdulhameed Odhar - Tel: 009647725300923; Email:
hodhar3@gmail.com; *Corresponding author


Article Type

Research Article



Received April 4, 2020; Revised April 12, 2020; Accepted April 12, 2020; Published May 31, 2020



The severe acute respiratory syndrome coronavirus-2, formerly known as 2019 novel coronavirus, is a pandemic public health threat. This beta coronavirus potentially infects the alveolar cells of the lung leading to pneumonia. The disease may progress into acute respiratory distress syndrome especially in elderly patients with comorbidities. Therefore, it is of interest to design and develop candidates for treatment, therapy and prevention. The spike glycoprotein of the virus known to potentially interact with angiotensin converting enzyme 2 as a cell entry receptor is a suitable candidate for further consideration as vaccine and treatment candidate. Hence, we screened the spike protein of coronavirus-2 for potential B-cell and T-cell epitopes for further deliberation. Thus, we document several peptides on the spike protein with predicted high antigenicity, low allergenicity and good stability against selected proteases. The linear B-cell epitope with sequence GFNCYFPLQSYGF is of particular interest in this context towards the design and development of short peptide vaccine candidates for combat and care against the virus.



SARS-CoV-2, 2019-nCoV, COVID-19, vaccine, epitope



Odhar et al. Bioinformation 16(5): 375-386 (2020)


Edited by

P Kangueane






Biomedical Informatics



This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.